LC-MS/MS Investigation of nitrosamine impurities in certain Sartan group medicinal products available in Istanbul, Türkiye Investigation des impuretés des nitrosamines par LC-MS/MS dans certains médicaments du groupe Sartan disponibles à Istanbul, Turquie

Öncü T., Yüksel B., Binay E., Şen N.

Annales Pharmaceutiques Francaises, vol.82, no.1, pp.72-83, 2024 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 82 Issue: 1
  • Publication Date: 2024
  • Doi Number: 10.1016/j.pharma.2023.08.002
  • Journal Name: Annales Pharmaceutiques Francaises
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, PASCAL, BIOSIS, Chemical Abstracts Core, Chimica, EMBASE, International Pharmaceutical Abstracts
  • Page Numbers: pp.72-83
  • Keywords: LC-MS/MS, Nitrosamines, Pharmaceutical analysis, Sartan medications, Validation
  • Police Academy Affiliated: Yes


Nitrosamines (NAs) are molecules that include the nitroso functional group. In 2018, the US Food and Drug Administration (FDA) received its first report of NAs in pharmaceuticals. The fact that NA impurities are likely human carcinogens is relevant to these compounds. Furthermore, prolonged exposure to NA contaminants above safe limits may raise the risk of cancer. The goal of this article was to assess the amounts of six different NAs in Sartan group medicines purchased from formal pharmacies in Istanbul, Türkiye, using a validated LC-MS/MS assay. An LC-MS/MS-based analytical assay was undertaken. The separation was performed with a HR ODS 150 mm × 3.0 mm and 5-analytical columns, providing effective separation of major peaks from NA impurities. In mobile phase A, formic acid was 0.10% in water, while in mobile phase B, formic acid was 0.10% in methanol. The flow rate was 0.4 mL/minute, and the total runtime was 18 minutes with the gradient elution mode. The validation was conducted in line with ISO/IEC 17025 requirements. Up to 100 μg/L, linearity was determined using correlation coefficients (r2 > 0.995) for all NAs. The limit of quantification values for all NAs analyses were below 1.0 μg/L. The mean recovery value obtained during the spike experiment was 95.18%, demonstrating the accuracy of the procedure. In addition, the accuracy was shown by a certified reference analysis, which yielded relative standard deviation and relative error values of 1.82% and 3.34%, respectively. During the intermediate precision testing, bias and relative standard deviation were 0.96 and 2.87%, respectively. Of the 75 study samples involving Sartan group medical products, no nitrosamine impurities were detected, demonstrating that pharmaceutical companies have adequate medication safety precautions in place in accordance with FDA and European Medicines Agency (EMA) regulations published to prevent NA contaminants in human medicinal products.